Avalo Therapeutics Goodwill

Avalo Therapeutics posts a goodwill of $11M as of June 2026. That compares with $11M in the prior-year period — up 0.0% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Avalo Therapeutics's goodwill was $11M. The latest reading is $11M — essentially flat versus a year earlier (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

Goodwill is one piece of Avalo Therapeutics's financial statement story. At $11M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for AVTX's goodwill usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Avalo Therapeutics's other metric pages and overview cover the third.

Judging Avalo Therapeutics against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in goodwill easier to interpret. Start with $11M here, then scan peer and history charts to see if the gap is persistent.